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Purpose
Although Korea has the highest incidence of gastric cancer worldwide and D2-lymphadenec-
tomies are routinely performed, radiotherapy (RT) practice patterns have not been well stud-
ied. Therefore, we examined RT usage trends for neoadjuvant/adjuvant patients and
identified factors associated with RT. We also examined survival benefits and net medical
cost advantages of adding RT. 
Materials and Methods
Patients diagnosed with gastric cancer who underwent gastrectomy from 2002-2013 were
identified using National Health Insurance Service-National Sample Cohort.
Results
Annually, 30.9 cases per 100,000 population in crude rate underwent gastrectomy in 230
hospitals and 49.8% received neoadjuvant/adjuvant therapy in 182 hospitals. For neo-
adjuvant/adjuvant patients, postoperative chemo-RT was administered in 4% of cases in
26 hospitals. No significant trends regarding treatment type were observed over time. Hav-
ing undergone RT was inversely associated with being ! 60 years old and having a low 
income. Having undergone RT was positively related to having a Charlson comorbidity index
! 4, hospital location and hospital volume (! 2,000 beds). Significant portions of patients
treated with RT in this nation (52%) were concentrated in one large-volume hospital. Use of
RT linked to increased cost of primary treatment, yet not to reduced overall medical expense.
RT did not influence both on overall and disease-specific survivals after adjusting for 
potential confounders (p > 0.05). 
Conclusion
RT was uncommonly utilized as adjuvant or neoadjuvant treatment by physicians in Korea.
Despite intrinsic drawback in this data, we did not find either survival benefit or net medical
cost advantage by adding RT in adjuvant treatment. 
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Introduction
Gastric cancer is the third leading cause of death among
men and the fifth leading cause of cancer death among
women worldwide [1]. Globally, 1,000,000 new cases of gas-
tric cancer are diagnosed annually, and half of these cases
occur in East Asia [2]. Korea has reported the highest inci-
dence of gastric cancer, along with Japan, and has an age-
standardized incidence of 56.8 cases per 100,000 men,
affecting nearly 30,000 patients in 2013 [3]. Complete surgical
resection is the primary therapy used, but a substantial num-
ber of patients with a more advanced stage disease (e.g., 
beyond submucosa or metastasis and into the lymph nodes)
experience locoregional, peritoneal, or systemic recurrences
after receiving curative gastrectomy alone [4]. Clinical trials
have been conducted to reduce the risk of recurrence and
mortality, but no international consensus concerning the best
oncological strategy has been reached [5,6]. 
The survival benefit of adjuvant chemoradiotherapy (CRT)
for curatively resected gastric cancer was established by the
Intergroup (INT)-0116 trial in 2001 [7]. However, recent data
from ARTIST and CRITICS trials showed that there was no
significant survival benefit in the CRT group over chemo-
therapy alone for D2-resected patients [8,9]. To date, several
underpowered studies have propounded an opinion that
some selected patients may still benefit from adding radio-
therapy (RT) to chemotherapy even after D2 surgery [10]. At
the same time, two multi-institutional phase III trials from
Korea and Japan demonstrated the merits of adjuvant che-
motherapy [11,12]. 
Given the controversial and limited data available, the role
of RT has been heavily criticized for gastric cancer patients
undergoing D2 gastrectomy, which has currently become the
standard of care in Europe and the United States as well as
in East Asia [13,14]. Furthermore, neither patterns of care nor
national data for RT specifically have been explored among
nonmetastatic gastric cancer patients in Korea. Therefore, the
purpose of this study was to examine RT usage trends for
neoadjuvant and adjuvant patients in Korea and to estimate
the impact of the available evidence on clinical practice using
data from a Korean national cohort from 2002 to 2013. Sec-
ondarily, we also examined survival benefits and net medical
cost advantages of adding RT in neoadjuvant and adjuvant
treatment.
Materials and Methods
All citizens in Korea are obligated to enroll in the single-
payer, national health insurance, and medical aid program
administered by the National Health Insurance Corporation.
The present study used data from the National Health Insur-
ance Service-National Sample Cohort (NHIS-NSC), which 
included 1,025,340 representative subjects (approximately
2.2% of the country’s population), who were randomly strat-
ified and selected based on age, sex, insurance type, income,
residential region, and individual total medical costs. Rates
were calculated and shown per 1,000,000 population. Details
of the NHIS-NSC database are available in a previous report
[15].
1. Data source and collection
The database includes information regarding basic patient
demographics, reimbursement for medical services, disease
codes according to the International Classification of Dis-
eases, 10th revision, identifiers for the clinic or hospital, med-
ical history, and mortality. This data is then automatically
linked to the Korean National Statistical Office where it is 
obtainable for research. This study which used data from the
NHIS-NSC was exempt from institutional review board eval-
uation; however, the study protocols adhere to the guidelines
outlined in the Declaration of Helsinki of 1964 and later ver-
sions in accordance with the ethical standards of the respon-
sible committee on human experimentation (institutional
and national). 
2. Description of the study cohort
Patients were eligible for analysis if they were diagnosed
with gastric cancer (ICD-10 code, C16), underwent gastrec-
tomy during the study period (2002-2013), and were > 20
years old at the time of diagnosis. We excluded patients who
had another primary cancer or known metastatic disease at
the time of diagnosis. In Korea, surgery alone is recom-
mended in patients with early gastric cancer and adjuvant or
neoadjuvant therapy is recommended in patients with stage
II-III gastric cancer. Treatments administered within 4 mon-
ths of surgery were considered as adjuvant or neoadjuvant.
The last follow-up was conducted in December 2013, and the
median follow-up time for patients who were still alive was
5.2 years (range, 0 to 11.9 years). 
3. Statistical analyses 
RT usage in the neoadjuvant and adjuvant setting was the
primary end-point. Patients were grouped into 2-year time
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epochs and the percentage of patients who received neoad-
juvant or adjuvant RT for each period from 2002 to 2013 were
calculated. Univariate and multivariate logistic regression
analyses were performed to investigate whether there was
an association between receipt of RT and sex, age (20-49, 
50-59, 60-69, or " 70 years), type of surgery (total vs. subtotal
gastrectomy), use of lymph node dissection, the Charlson 
comorbidity index (sum of weights assigned to predeter-
Table 1. Demographic characteristics of gastric cancer patients who underwent gastrectomy with or without neoadjuvant/
adjuvant treatment from 2002 to 2013 
Characteristic Total Neoadjuvant/ Neoadjuvant/ p-valueAdjuvant (–)a) Adjuvant (+)a)
Sex
Male 2,436 (67) 1,209 (66) 1,227 (67) 0.320
Female 1,217 (33) 625 (34) 592 (33)
Age (yr)
20-49 770 (21) 384 (21) 386 (21) 0.008
50-59 901 (25) 442 (24) 459 (25)
60-69 1,110 (30) 529 (29) 581 (32)
70-89 872 (24) 480 (26) 392 (22)
Surgery type
TG 822 (23) 305 (17) 517 (28) < 0.001
STG/PG 2,831 (77) 1,529 (83) 1,302 (72)
LND use
No 83 (3) 39 (2) 44 (3) 0.523
Yes 3,213 (97) 1,602 (98) 1,610 (97)
Charlson comorbidity index
0-1 2,216 (61) 1,077 (59) 1,139 (63) 0.054
2 702 (19) 375 (20) 327 (18)
3 316 (9) 172 (9) 144 (8)
" 4 419 (11) 211 (11) 209 (11)
Income
! 20 percentile 562 (15) 285 (16) 277 (15) 0.015
21-80 percentile 1,917 (52) 923 (50) 995 (55)
" 81 percentile 1,174 (32) 627 (34) 547 (30)
Health insurance type
NHI 3,532 (97) 1,770 (96) 1,761 (97) 0.556
Medical aid 122 (3) 64 (4) 58 (3)
Residential area
Metropolitan 1,663 (46) 804 (44) 859 (47) 0.035
Non-metropolitan 1,991 (54) 1,031 (56) 960 (53)
Hospital location
Metropolitan 3,161 (87) 1,567 (85) 1,594 (88) 0.051
Non-metropolitan 493 (13) 267 (15) 225 (12)
Hospital volume (beds)
< 1,000 1,503 (41) 738 (40) 765 (42) 0.265
" 1,000 2,151 (59) 1,096 (60) 1,054 (58)
Disabled status
No 3,295 (90) 1,641 (89) 1,654 (91) 0.132
Yes 358 (10) 193 (11) 165 (9)
Values are presented as number (%). TG, total gastrectomy; STG/PG, subtotal gastrectomy/partial gastrectomy; LND, lymph
node dissection; NHI, National Health Insurance. a)Patients who received chemotherapy and/or radiotherapy before and after
the surgery within 3 months were considered as (neo-)adjuvant group. 
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mined clinical conditions which were collected from in- and
out-patient billing data within the diagnosis year; charlson
comorbidity index (CCI); 0-1, 2, 3, or " 4) [16], income per-
centile (< 20, 20-79, or " 80), health insurance type, residential
and hospital location (metropolitan or not), hospital volume
(< 1,000, 1,000-1,999, or " 2,000 beds), and disability status.
Scatter plots were used to examine practice patterns in rela-
tion to hospital volume as a function of XY position. A met-
ropolitan location referred to cities with more than 1,000,000
people. 
We also examined the use of preoperative or postoperative
chemotherapy among neoadjuvant and adjuvant patients,
the overall incidence of perioperative mortality (patients who
died within 1 month of surgery), overall survival (OS; from
diagnosis to any cause of death), and disease-specific sur-
vival (DSS; from diagnosis to gastric cancer-specific death).
OS and DSS were estimated using the Kaplan-Meier method.
A Cox proportional hazards survival analysis was performed
to identify hazard ratios and 95% confidence intervals (CI).
We calculated direct total medical costs as the sum of inpa-
tient and outpatient services based on claim and reimburse-
ment data by medical service providers from 2002 to 2013.
Primary treatment and net medical costs were defined and
calculated as medical bill expenses claimed by medical serv-
ice providers from diagnosis to 3 months’ postsurgery and
to death/last follow-up, respectively. All costs are presented
in U.S. dollars, with an exchange rate of 1,103 Korean won
to 1 U.S. dollar, which was the annual average exchange rate
in 2008. A threshold of p=0.05 was selected for statistical sig-
nificance. All statistical analyses were performed using SPSS
ver. 20.0 (IBM SPSS Statistics, IBM Corp., Armonk, NY).
Results
1. Sociodemographic characteristics
The baseline sociodemographic characteristics of gastric
cancer patients who underwent gastrectomy are described in
Table 1 (a more detailed explanation is provided in Supple-
mentary Results, S1 Fig.). An analysis of the demographic
characteristics by year revealed that patients who were older,
had more comorbid diseases, received medical aid, and was
disabled were more likely to undergo surgery from nonmetro-
politan hospitals at the end of the study period than at the 
beginning (all p < 0.05) (S2 Table).
2. Postoperative mortality
The overall 1-month postoperative mortality rate was 0.6%.
Higher mortality rates were observed in patients > 70 years
old (1.2%, p=0.039), those with a CCI " 4 (1.6%, p=0.027), and
those who underwent total gastrectomy (1.1%, p=0.038) 
(S3 Table). Hospital volume was also significantly associated
with mortality rate (< 1,000, 1,000-1,999, and " 2,000; 0.8%,
0.7%, and 0.0%, respectively; p=0.018), and patients with a low 
income (! 20th percentile), who received medical aid, or who
underwent postoperative chemotherapy had a doubled mor-
tality rate, although this was not statistically significant (all 
p > 0.05). 
3. Neoadjuvant or adjuvant treatment
Almost half (49.8%) of patients who underwent gastrectomy
received adjuvant or neoadjuvant chemotherapy. Between
2002 and 2013, the number of patients who received neoadju-
vant or adjuvant treatment decreased by 26% (from 64% to
38%) (S4 Fig.). However, this may be because of decreases in
the number of cases of advanced gastric cancer resulting from
Table 2. Trends in neoadjuvant or adjuvant treatment by the group from 2002 to 2013 
Year Adjuvant Adjuvant Neoadjuvant Neoadjuvant    p-valuea)chemotherapy chemo-RT chemotherapy chemo-RT
2002-2003 311 (89.1) 8 (2.2) 30 (8.7) 0 ( 0.078
2004-2005 296 (87.1) 15 (4.3) 29 (8.6) 0 (
2006-2007 274 (87.5) 10 (3.1) 29 (9.3) 0 (
2008-2009 248 (87.9) 16 (5.5) 19 (6.6) 0 (
2010-2011 227 (83.2) 17 (6.1) 25 (9.3) 4 (1.4)
2012-2013 223 (85.4) 9 (3.4) 28 (10.8) 1 (0.4)
Total 1,580 (86.9) 73 (4.0) 161 (8.8) 5 (0.3)
Values are presented as number (%). RT, radiotherapy. a)The linear-by-linear association test was used to examine trends over
time. 
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the nationwide gastric cancer screening and surveillance pro-
gram implemented in 1999 (a more detailed explanation is
provided in Supplementary Results) [17]. Also, the neoadju-
vant/adjuvant treatment group displayed similar sociodemo-
graphic characteristics by year relative to those of entire cohort
(S2 and S5 Tables and S6 Fig.). 
4. Patterns of neoadjuvant and adjuvant treatment 
Postoperative adjuvant chemotherapy was administered in
most cases (86.9%), followed by neoadjuvant chemotherapy
(8.8%), adjuvant CRT (4%), and neoadjuvant CRT (0.3%). The
sociodemographic characteristics of patients who received RT
did not change significantly by year. No trends were found
regarding treatment modality by year among any of the four
treatment groups (Table 2). The number of patients receiving
neoadjuvant chemotherapy increased (by 4.2%) from 2008-
2009 to 2012-2013. The opposite trend was noted in the adju-
vant chemotherapy and adjuvant CRT groups (from 87.9%
and 5.5% in 2008-2009 to 85.4% and 3.4% in 2012-2013, respec-
tively). 
5. Factors associated with receipt of RT 
Having undergone RT was inversely associated with being
" 60 years old and having a low income (! 20th percentile).
Having undergone RT was positively associated with having
a CCI " 4 and hospital location (nonmetropolitan). Hospital
volume (" 2,000 beds) was found to be the strongest factor 
affecting the use of RT (vs. < 1,000 beds; adjusted odds ratio,
7.62; 95% CI, 3.95 to 14.71) (Table 3). 
Among 230 hospitals, only 26 hospitals (12.1%) used RT,
and the median proportion of RT use in neoadjuvant and 
adjuvant patients in each hospital was 4.1% (Fig. 1A). Addi-
tionally, one large hospital used RT with chemotherapy
(47.6%) as often as chemotherapy alone (47.6%) in that hospital
and seemed to care for a significant portion of the RT patients
in the nation (52%). 
On the other hand, neoadjuvant chemotherapy was used in
74 hospitals (34.6%), and the median proportion of neoadju-
vant chemotherapy use among neoadjuvant/adjuvant pati-
ents in each hospital was 7.5% (Fig. 1B). Adjuvant chemo-
therapy was used in nearly all hospitals (98.6%), and an aver-
age of 90.9% of neoadjuvant/adjuvant patients received adju-
vant chemotherapy in each hospital (Fig. 1C). 
6. Costs
The mean cost for primary treatment was $7,437 per patient
of neoadjuvant/adjuvant treatment. The average net cost from
diagnosis to death or last follow-up was $13,965 per patient.
Costs by various subgroups are presented in Table 4. PrimaryVa
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treatment costs were higher for patients with total gastrectomy
(vs. subtotal), a higher CCI (3 or " 4), disabled status, RT, and
from a large volume hospital (all p < 0.05). Total medical costs
were higher for patients with total gastrectomy (vs. subtotal),
a higher CCI (3 or " 4), RT, from a high-income group (" 81
percentile), and from a large volume hospital (all p < 0.05).
Elderly was found to be related to lower total medical cost.
The mean costs of primary treatment were $3,734 per person
higher for patients who received RT with chemotherapy than
those receiving chemotherapy alone. This cost difference was
sustained and even more pronounced when it came to net
medical cost ($6,884 per person). 
7. Survival analyses 
Patients who underwent gastrectomy and received adjuvant
or neoadjuvant therapies for gastric cancer in Korea showed
a 5-year OS of 66.5% (95% CI, 64.2 to 68.9) and a 5-year DSS of
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Fig. 1.  Bubble charts for the proportion of patients by the hospital. Two-dimensional bubble charts indicate how the pro-
portions of adjuvant chemoradiotherapy (A), neoadjuvant chemotherapy (B), and adjuvant chemotherapy use (C) in each
hospital change by hospital volume. The size of the bubble corresponds to the proportion within each treatment group. RT,
radiotherapy.
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Table 4. Kaplan-Meier estimated 5-year survival rate and mean cost for gastric cancer patients who underwent gastrectomy
and neoadjuvant/adjuvant treatment from 2002 to 2013, overall and subgroup by demographic characteristics and the receipt
of radiation therapy 
No. Cost of primary p-value Net medical p-value 5-Year 5-Year treatment ($)a),b) cost ($)b),c) OS (%) DSS (%)
Sex
Male 1,227 8,713±216 0.339 16,097±406 0.458 65.8 71.1
Female 592 8,351±309 15,572±574 68.2 71.3
Age (yr)
20-49 386 7,941±294 0.263 16,175±678 0.026 72.3 72.5
50-59 459 8,730±346 16,980±709 72.7 75.6
60-69 581 8,688±321 16,146±638 65.8 71.2
70-89 392 8,946±445 14,117±570 54.7 64.2
Surgery type
TG 517 11,513±398 < 0.001 20,868±699 < 0.001 48.5 52.1
STG 1,302 7,437±181 13,965±357 73.7 78.6
Charlson comorbidity index
0-1 1,139 7,575±187 < 0.001 14,787±385 < 0.001 67.5 69.9
2 327 8,892±346 16,632±715 69.3 72.7
3 144 11,193±890 18,792±1,426 67.6 80.3
" 4 209 12,416±812 19,418±1,350 55.1 71.9
Income
! 20 percentile 277 8,621±438 0.402 14,731±763 0.040 64.7 68.3
21-80 percentile 995 8,398±217 15,600±429 68.4 73.1
" 81 percentile 547 8,940±375 17,125±674 64.1 69.1
Health insurance type
NHI 1,761 8,591±181 0.893 16,029±339 0.089 67.1 71.8
Medical aid 58 8,727±766 12,814±1,421 48.5 48.5
Residential area
Metropolitan 859 8,687±283 0.622 16,089±479 0.643 66.9 71.7
Non-metropolitan 960 8,513±219 15,781±459 66.2 70.7
Hospital location
Metropolitan 1,594 8,575±194 0.697 15,770±344 0.207 66.9 71.5
Nonmetropolitan 225 8,742±382 17,045±1,120 63.9 68.4
Hospital volume (beds)
< 1,000 765 8,892±256 0.017 14,172±507 0.034 64.6 69.6
1,000-1,999 707 7,978±260 13,978±519 71.2 75.1
" 2,000 347 9,201±506 15,111±801 61.4 66.4
Disabled status
No 1,654 8,422±172 0.041 15,858±346 0.511 66.9 71.1
Yes 165 10,327±908 16,617±1,146 62.9 71.5
RT use
No 1,741 8,441±180 < 0.001 15,642±337 < 0.001 67.1 71.4
Yes 78 12,175±792 22,526±1,623 58.0 68.7
Death during study
Yes 607 11,234±422 < 0.001 24,160±701 < 0.001 - -
No 1,212 7,274±147 11,804±288 - -
OS, overall survival; DSS, disease-specific survival; TG, total gastrectomy; STG, subtotal gastrectomy; NHI, National Health
Insurance; RT, radiotherapy. a)Defined as medical bill expenses claimed by medical service providers for primary treatment,
b)All costs are presented in U.S. dollars, with an exchange rate of 1,103 Korean won to 1 U.S. dollar, which was the annual 
exchange rate in 2008, c)Defined as medical bill expenses claimed by medical service providers from diagnosis to death or last
follow-up.
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71.1% (95% CI, 68.8 to 73.5). Compared with patients received
chemotherapy alone, those who received CRT had inferior 
5-year OS (p=0.020) (Table 4). However, the 5-year DSS was
similar according to the use of RT (no RT vs. RT; 71.4% vs.
68.7%, p=0.347), which is understandable given the high pro-
portion of comorbid patients in RT group. Being older (" 60
years), having a total gastrectomy, having a higher CCI (4),
and receiving medical aid were significantly related to worse
survival (S7 and S8 Tables).
Discussion
This study highlights the national patterns of neoadjuvant
and adjuvant RT use for gastrectomy patients in Korea as
well as the sociodemographic factors associated with its use.
The results showed that RT usage was exceedingly low and
primarily concentrated in one large-volume hospital. In com-
parison, there was a low rate of, but growing interest in,
neoadjuvant chemotherapy (one-third of the hospitals in the
nation). Adjuvant chemotherapy accounted for about 90% of
the therapy modalities used and was mainstream in nearly
all hospitals. These practice patterns are concerning given
that RT, which has already been verified and accepted as an
essential adjuvant therapy modality for gastric cancer in the
Unites States [18], has not had enough opportunity to 
develop the evidence in D2-dissected patients. 
We found that only 4% of patients received RT as an adju-
vant or neoadjuvant treatment. Furthermore, our results con-
tradict the results of the previous Surveillance, Epidemio-
logy, and End Results studies [19]. For example, in the
United States, the proportion of patients who underwent sur-
gery alone after 2000 decreased by at least 13%, but the pro-
portion of patients who underwent CRT increased from
8%-14% to 25%-33%. This implies that, in Korea, the results
of the INT-0116 trial, unlike in the United States [19,20], did
not affect treatment practices. 
The discrepancy between patterns and trends in the United
States and Korea may be explained by the extent and safety
of lymphadenectomies performed in East Asia [21]. Accord-
ing to the 2004 the Korean Gastric Cancer Association
(KGCA) nationwide survey, the quality of extensive D2 lym-
phadenectomy, represented by the number of retrieved
lymph nodes, was assured in most of the 57 hospitals belong-
ing to the KGCA regardless of hospital volume [22]. In con-
trast to the high postoperative mortality rate (~10%) in trials
conducted in Western countries [23-25], the very low mor-
tality rate (< 1%) for D2 dissection observed in prior Phase
III trials in Korea [12] and Japan [26] was reaffirmed on a
population level in the present study (0.6%). Although we
found that patients who were " 70 years old, had a high 
comorbidity burden (CCI " 4), and who had a more severe
cancer stage (having undergone total gastrectomy) were 
associated significantly, we found only a slight increase in
the risk of postoperative mortality. 
In addition, our data showed that the majority of RT 
patients were concentrated in one large-volume hospital [8].
The proportion of RT administered in this hospital was
greater in magnitude (52%) than the proportion of RT admin-
istered in all other 25 hospitals combined. Otherwise, RT was
more likely to be utilized in small- or medium-volume hos-
pitals located in nonmetropolitan areas. Although we were
not able to investigate whether tumor factors, such as cancer
stage or adverse pathologic features, influenced the consid-
eration of RT, we found significant interhospital variations
(Fig. 1A). This indicates that cultural predispositions rather
than universal criteria guide clinical decisions. 
Furthermore, being over 60 years old and having a low 
income (! 20th percentile) were barriers to receiving RT. On
the other hand, we found that patients with a high comor-
bidity burden were more likely to receive RT. This is most
likely because trimodal therapy including RT is used for 
patients who may be intolerant to full-dose chemotherapy,
such as those with a high comorbidity burden. In our opin-
ion, studies are needed to determine the role of RT in the clin-
ical setting among patients that might be intolerant to
full-dose chemotherapy. 
Moreover, the absolute proportion of patients receiving
adjuvant chemotherapy ranged 83.2%-89.1%. Furthermore,
the 5-year OS and the 5-year DSS outcomes in this study
(66.5% and 71.5%, respectively) were consistent or lower
when compared to the Capecitabine and Oxaliplatin Adju-
vant Study in Stomach Cancer (CLASSIC) [12] and the 
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer
(ACTS-GC) [11] trials; however, these two trials included
younger patients with fewer comorbidities than observed in
the general population, which may account for any discrep-
ancies. The overwhelming use of adjuvant chemotherapy
found in our study might be rooted, to some degree, in a
propensity for clinicians to depend heavily on evidence gen-
erated from our country. Nevertheless, this consistent usage,
which existed before 2007, is worrisome because it may 
indicate that these practices were determined before matu-
ration of emerging evidence. 
The addition of RT to adjuvant/neoadjuvant chemother-
apy increased the mean cost of $3,734 in Korea that has sin-
gle-payer health care system. We could not find that addition
of RT reduced the net medical cost during follow-up that 
indirectly reflected recurrence preventing treatment effects.
In addition, it was found that RT did not increase the 5-year
DSS rate (RT vs. no RT, 68.7% vs. 71.4%), yet consistent with
previous findings of ARTIST trial (5-year OS, 75% vs. 73%)
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and CRITICS trial (5-year OS, 40.9% vs. 41.3%). Although we
felt that use of RT in (neo-)/adjuvant setting (before)/after
D2 surgery increased the total medical cost but not the sur-
vival rate in these general population, such a precondition
would require (1) that the clinical indication was not differ-
ent between patients with CRT and those with chemotherapy
alone, and (2) that all other confounders, which were not
identified in this study, were well balanced. Although pre-
vious reports imply the fulfillment of preconditions [27], we
cannot justify these findings without details including tumor
stage or residual tumor burden, but may question the impor-
tance and necessity of RT in D2-dissected patients [28]. How-
ever, several studies have demonstrated  loco-regional recurr-
ence usually occurs in the nodal basin outside the D2 dissec-
tion surgical field [28,29] and a considerable rate of  loco-
regional recurrence is observed in high-risk patients (e.g.,
N+) even after D2 surgery [30]. In the ARTIST trial, there was
a significant benefit in a subgroup of patients with N+ with
postoperative CRT. A subsequent ARTIST II trial is currently
underway to refine the role of RT in patients with positive
lymph node metastasis. 
We also found that sociodemographic factors such as being
" 60 years old, having a high comorbidity burden, and 
receiving medical aid were associated with poorer survival
outcomes. Therefore, when making treatment decisions for
individual patients, physicians should consider sociodemo-
graphic factors. 
The current study has some limitations. For example, the
NHIS-NSC database lacks information on gastric cancer stag-
ing and recurrence; therefore, the analyses of stage-specific
patterns of care and the impact of neoadjuvant and adjuvant
treatment on survival were limited. In our study, standard-
ized incidences were not calculated, as the Korean Statistical
Information Service do not provide the incidence informa-
tion of the intersection of two sets (diagnosed as gastric can-
cer and underwent gastrectomy).  Since our findings were
computed in the crude rates which result from the specific
composition which prevails in our sampled population, we
caution against direct comparing other study populations
with respect to actual numerical values. We also lacked direct
clinical data regarding pathologic factors (such as residual
tumor burden), radiation specifics (e.g., dose, fractionation,
and field), performance status, and treatment compliance. 
Information on chemotherapy regimen was also unavailable
for some patients, further limiting the analyses of chemother-
apy patterns of care. Therefore, further studies examining the
impact of RT on survival in well-designed prospective trials
as well as in the general population are necessary. However,
despite these limitations, this study also has a strength that
the NHIS-NSC database represents nearly all patients in
Korea, allowing us to generalize to the entire population in
Korea.
The present study is the first large study to analyze the use
of RT in the neoadjuvant and adjuvant management of gas-
tric cancer in East Asia. We observed that RT was uncom-
monly utilized and that RT patients were concentrated
heavily in one hospital. Considering the sizable cost overrun
and lack of survival advantage for RT in general population,
better risk stratifying D2-dissected patients is utterly critical
to refine the role of RT in D2-dissected patients. It is impor-
tant to recognize the cultural predispositions highlighted in
our study since they might continue to influence physician
practices and attitudes toward RT, despite emerging evi-
dence. 
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